Habitual snoring due to adenotonsillar hypertrophy in children who receive medical treatment habitual snoring, adenotonsillar hypertrophy, obstructive sleep apnea, treatment failure
Conditions
Interventions
children who had a snoring of less than 3 days/week after medical treatment.,children who had a snoring equal or greater than 3 days/week and/or persistent OSA-related symptoms (gasping, daytime sleep
Treatment,Treatment
Clinical success,Clinical failure
Sponsors
Chulalongkorn University
Eligibility
Sex/Gender
All
Age
1 Years to 15 Years
Inclusion criteria
Inclusion criteria: 1. Children aged 1-15 years who had habitual snoring (equal or more than 3 days per week) due to ATH 2. initially received medical treatment, which was intranasal corticosteroids and/or montelukast.
Exclusion criteria
Exclusion criteria: 1. craniofacial anomalies (e.g., Pierre-Robin sequence, syndromic craniosynostoses, and Treacher Collins syndrome) 2. Down syndrome 3. Prader-Willi syndrome, and 4. Neuromuscular conditions. 5. Children who were treated with other modalities, including adenotonsillectomy and non-invasive positive pressure ventilation (continuous positive airway pressure or bilevel-positive airway pressure) during the medical treatment 6. Children who were lost to follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical failure 6 weeks Symptoms (gasping, daytime sleepiness, hyperactivity, apnea, nocturnal enuresis, cyanosis, or fatigue) | — |
Secondary
| Measure | Time frame |
|---|---|
| Factors associated with clinical failure 6 weeks Symptoms (gasping, daytime sleepiness, hyperactivity, apnea, nocturnal enuresis, cyanosis, or fatigue) | — |
Countries
Thailand
Contacts
Public ContactWatit Niyomkarn
Chulalongkorn University
Outcome results
None listed